Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Free Report) CFO Avraham Gabay sold 73,360 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $4.51, for a total transaction of $330,853.60. Following the transaction, the chief financial officer directly owned 671,785 shares of the company’s stock, valued at $3,029,750.35. The trade was a 9.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Oramed Pharmaceuticals Stock Down 0.2%
Shares of Oramed Pharmaceuticals stock opened at $4.60 on Friday. Oramed Pharmaceuticals Inc. has a twelve month low of $1.98 and a twelve month high of $5.19. The company’s 50 day moving average is $4.10 and its 200 day moving average is $3.63. The company has a market cap of $188.28 million, a price-to-earnings ratio of 1.78 and a beta of 1.21.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings raised Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, June 11th. One analyst has rated the stock with a Hold rating, According to MarketBeat.com, Oramed Pharmaceuticals currently has an average rating of “Hold”.
Institutional Trading of Oramed Pharmaceuticals
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE raised its position in Oramed Pharmaceuticals by 2.7% in the first quarter. Bank of America Corp DE now owns 146,152 shares of the biotechnology company’s stock worth $497,000 after acquiring an additional 3,909 shares during the period. OMERS ADMINISTRATION Corp bought a new stake in shares of Oramed Pharmaceuticals during the 1st quarter valued at $63,000. Dimensional Fund Advisors LP grew its position in shares of Oramed Pharmaceuticals by 5.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 158,209 shares of the biotechnology company’s stock valued at $538,000 after acquiring an additional 7,738 shares during the period. Hillsdale Investment Management Inc. bought a new stake in shares of Oramed Pharmaceuticals during the 1st quarter valued at $331,000. Finally, Kathmere Capital Management LLC purchased a new stake in shares of Oramed Pharmaceuticals in the 1st quarter worth $51,000. 12.73% of the stock is owned by hedge funds and other institutional investors.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.
The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.
See Also
- Five stocks we like better than Oramed Pharmaceuticals
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
